FAP and cancer: Use of the radiolabeled FAP inhibitor (FAPi) [68Ga]-FAPi-46 PET has demonstrated heterogeneous localization of FAP in tumors in a clinical trial and will be further explored as a pan-cancer imaging biomarker for FAP expression and as a stratification tool for FAP-targeted therapies [222].